• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

透皮芬太尼:药代动力学及初步临床评估

Transdermal fentanyl: pharmacokinetics and preliminary clinical evaluation.

作者信息

Plezia P M, Kramer T H, Linford J, Hameroff S R

机构信息

Department of Pharmacy Practice, College of Pharmacy, University of Arizona, Tucson 85721.

出版信息

Pharmacotherapy. 1989;9(1):2-9. doi: 10.1002/j.1875-9114.1989.tb04096.x.

DOI:10.1002/j.1875-9114.1989.tb04096.x
PMID:2646620
Abstract

A new transdermal drug-delivery system that administers the synthetic opioid fentanyl through intact skin was evaluated for 24 hours postoperatively in eight patients who had undergone orthopedic surgery. Plasma samples were obtained over a 72-hour period for pharmacokinetic analysis in five patients. The patients were also evaluated intensively for adequacy of analgesia, frequency of nausea and sedation, and occurrence of ventilatory depression. A median lag time of 2.25 hours after application of the transdermal system was observed before the appearance of fentanyl in the blood. Median peak concentration and time to peak were 1.0 ng/ml and 22 hours, respectively. The apparent elimination of fentanyl after transdermal administration is prolonged relative to previously reported values. Absorption analysis indicates zero-order fentanyl administration, and in addition, suggests deposition of drug in an epidermal site, with the resultant prolonged absorption process giving the appearance of slow elimination. No significant toxicities were observed. Four patients required no additional analgesia. No consistent correlations among fentanyl concentration and any clinical values were observed. Transdermal administration of fentanyl appears to be a viable alternative to conventional routes of narcotic administration and warrants further study.

摘要

一种通过完整皮肤给药合成阿片类药物芬太尼的新型透皮给药系统,在8例接受骨科手术的患者术后进行了24小时评估。在5例患者中,在72小时内采集血浆样本进行药代动力学分析。还对患者进行了深入评估,包括镇痛效果、恶心和镇静频率以及通气抑制的发生情况。在透皮系统应用后,观察到芬太尼在血液中出现前的中位滞后时间为2.25小时。中位峰值浓度和达峰时间分别为1.0 ng/ml和22小时。与先前报道的值相比,透皮给药后芬太尼的表观消除时间延长。吸收分析表明芬太尼给药为零级,此外,提示药物沉积在表皮部位,由此产生的延长吸收过程导致消除缓慢。未观察到明显毒性。4例患者无需额外镇痛。未观察到芬太尼浓度与任何临床值之间存在一致的相关性。芬太尼透皮给药似乎是传统麻醉给药途径的一种可行替代方法,值得进一步研究。

相似文献

1
Transdermal fentanyl: pharmacokinetics and preliminary clinical evaluation.透皮芬太尼:药代动力学及初步临床评估
Pharmacotherapy. 1989;9(1):2-9. doi: 10.1002/j.1875-9114.1989.tb04096.x.
2
Biopharmaceutics of a new transdermal fentanyl device.一种新型透皮芬太尼装置的生物药剂学
Anesthesiology. 1995 Sep;83(3):459-69. doi: 10.1097/00000542-199509000-00004.
3
The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat.经皮给予芬太尼并伴有或不伴有控温时的药代动力学。
J Pain. 2003 Aug;4(6):291-7. doi: 10.1016/s1526-5900(03)00618-7.
4
Comparison of plasma fentanyl concentrations by using three transdermal fentanyl patch sizes in dogs.使用三种不同尺寸的透皮芬太尼贴剂对犬血浆芬太尼浓度的比较。
Vet Surg. 1998 Mar-Apr;27(2):159-66. doi: 10.1111/j.1532-950x.1998.tb00114.x.
5
Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control.透皮芬太尼。其药理特性及疼痛控制治疗效果综述。
Drugs. 1997 Jan;53(1):109-38. doi: 10.2165/00003495-199753010-00011.
6
Comparison of pharmacokinetics of fentanyl after intravenous and transdermal administration in cats.猫静脉注射和经皮给药后芬太尼的药代动力学比较。
Am J Vet Res. 2000 Jun;61(6):672-7. doi: 10.2460/ajvr.2000.61.672.
7
Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain.透皮芬太尼治疗慢性疼痛的获益-风险评估。
Drug Saf. 2003;26(13):951-73. doi: 10.2165/00002018-200326130-00004.
8
Pharmacokinetics of fentanyl after intravenous and transdermal administration in goats.山羊静脉注射和经皮给药后芬太尼的药代动力学
Am J Vet Res. 1999 Aug;60(8):986-91.
9
Opioid plasma concentrations during a switch from transdermal fentanyl to methadone.从透皮芬太尼转换为美沙酮期间的阿片类药物血浆浓度。
J Palliat Med. 2007 Apr;10(2):338-44. doi: 10.1089/jpm.2006.0140.
10
Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control.透皮芬太尼:其药理特性及在慢性癌痛控制中的治疗效果的最新综述
Drugs. 2001;61(15):2289-307. doi: 10.2165/00003495-200161150-00014.

引用本文的文献

1
Influence of aprepitant and localization of the patch on fentanyl exposure in patients with cancer using transdermal fentanyl.阿瑞匹坦及贴片位置对使用透皮芬太尼的癌症患者芬太尼暴露量的影响。
Oncotarget. 2018 Apr 6;9(26):18269-18276. doi: 10.18632/oncotarget.24812.
2
Formulations of fentanyl for the management of pain.芬太尼制剂用于疼痛管理。
Drugs. 2010;70(1):57-72. doi: 10.2165/11531740-000000000-00000.
3
[Transdermal fentanyl for the treatment of cancer pain.].[透皮芬太尼用于治疗癌痛。]
Schmerz. 1993 Mar;7(1):18-24. doi: 10.1007/BF02527634.
4
Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain.透皮芬太尼治疗慢性疼痛的获益-风险评估。
Drug Saf. 2003;26(13):951-73. doi: 10.2165/00002018-200326130-00004.
5
Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl.经皮阿片类药物的临床药代动力学:聚焦于经皮芬太尼
Clin Pharmacokinet. 2000 Jan;38(1):59-89. doi: 10.2165/00003088-200038010-00004.
6
Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control.透皮芬太尼。其药理特性及疼痛控制治疗效果综述。
Drugs. 1997 Jan;53(1):109-38. doi: 10.2165/00003495-199753010-00011.
7
Pharmacotherapy of opioids: present and future developments.阿片类药物的药物治疗:现状与未来发展
Pharm World Sci. 1996 Jan;18(1):1-15. doi: 10.1007/BF00449683.
8
Day-to-day titration of transdermal fentanyl is unwise.对透皮芬太尼进行日常滴定是不明智的。
Support Care Cancer. 1995 May;3(3):210-1. doi: 10.1007/BF00368895.
9
Novel drug delivery systems. An overview of their impact on clinical pharmacokinetic studies.新型药物递送系统。其对临床药代动力学研究影响的概述。
Clin Pharmacokinet. 1991 Jan;20(1):1-14. doi: 10.2165/00003088-199120010-00001.